西洛他唑与噻氯匹定预防冠心病支架置入术后冠状动脉再狭窄的效果对比A randomized trial of cilostazol versus ticlopidine for anti-platelet therapy after coronary artery stenting for prevention of restenosis
洪斌,钱菊英,樊冰,金雪娟,葛均波
摘要(Abstract)：
目的评价西洛他唑对冠状动脉支架术后再狭窄的影响。方法150例行冠状动脉支架术的患者随机分为西洛他唑组(试验组)和噻氯匹定组(对照组)。两组患者于术前48 h开始服用西洛他唑200 mg/d或噻氯匹定500 mg/d,西洛他唑组术后持续服药6个月,噻氯匹定组服药4周,并分别加用阿司匹林100 mg/d至术后6个月。出院后定期门诊随访,术后6个月复查冠状动脉造影。结果在随访中,试验组严重心脏事件发生率和严重药物副反应较对照组少。试验组和对照组在支架术后6个月造影中最小管径(2.24±1.16 mm比2.04±1.24 mm)、实际管径获得(2.73±0.45 mm比2.78±0.46 mm)、最终管径丢失(0.90±1.05 mm比1.06±1.14 mm)、丢失指数(0.34±0.40比0.38±0.40)和再狭窄率(28.0%比36.7%)差异均无统计学意义。结论西洛他唑在冠状动脉支架置入后预防急性或亚急性血栓并发症和降低晚期再狭窄率与噻氯匹定具有接近的作用,对于不能耐受噻氯匹定的患者,西洛他唑可以作为替代药物。
关键词(KeyWords)： 血管成形术,经腔,经皮冠状动脉;血小板聚集抑制剂;西洛他唑;噻氯匹定
基金项目(Foundation):
作者(Author): 洪斌,钱菊英,樊冰,金雪娟,葛均波
参考文献(References)：
- [1]Cecena FA.Stenting stent:alternative strategy for treating instentrestenosis.Cathet Cardiovasc Diagn,1996,39:377-382.
- [2]Ge JB,Han YL,Jiang H,et al.A Prospective Randomized Anti-platelet Trial of Cilostazol vs.Ticlopidine in Patients Undergoing Cor-onary Stenting:long-term clinical and angiographic outcome.J CardioPhar 2005,46:162-166.
- [3]Hobson RW,Howard VJ,Roubin GS,et al.Carotid artery stentingis associated with increased complications in octogenarians:30-daystroke and death rates in the CREST lead-in phase.J Vasc Surg,2004,40:1106-1111.
- [4]Kamishirado H,Inoue T,Mizoguchi K,et al.Randomized compari-son of cilostazol versus ticlopidine hydrochloride for antiplatelet thera-py after coronary stent implantation for prevention of late restenosis.Am Heart J,2002,144:303-308.